Table 7. [11C]-(+)-PHNO BPND and −ΔBPND (%) (Mean±SD) Values Across Three Baboons for Antipsychotic Study.
| Region |
BPND |
−ΔBPND (%) |
|||
|---|---|---|---|---|---|
| Baseline | CLZ | HAL | CLZ | HAL | |
| Putamen | 2.41±0.40 | 1.38±0.28 | 0.74±0.36 | 43±11 | 70±14 |
| Caudate | 2.37±0.51 | 1.35±0.32 | 0.75±0.31 | 44±10 | 69±13 |
| VST | 3.57±1.15 | 2.76±0.74 | 1.18±0.39 | 24±17 | 66±18 |
| GP | 5.54±1.73 | 4.30±0.71 | 2.12±0.76 | 21±14 | 61±14 |
| SN/VTA | 1.27±0.26 | 1.23±0.33 | 0.77±0.61 | 7±12 | 39±50 |
| Thalamus | 1.12±0.25 | 0.99±0.21 | 0.79±0.86 | 14±10 | 31±75 |
Abbreviations: GP, globus pallidus; SN/VTA, substantia nigra/ventral tegmental area; VST, ventral striatum.
Baselines are averages of three scans (two subjects) or two scans (one subject). Post-drug scans are average of two scans per drug for every subject. ΔBPND for each subject is relative to the average of that subject's baseline BPND.